Article info

PDF

Original Article
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment

Authors

  1. Correspondence to Dr Behzad Najafian, Department of Pathology, University of Washington, Box 356100, 1959 NE Pacific St, Seattle, WA 98195, USA; najafian{at}uw.edu
View Full Text

Citation

Mauer M, Sokolovskiy A, Barth JA, et al
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment

Publication history

  • Received 19 May 2017
  • Revised 15 June 2017
  • Accepted 19 June 2017
  • Published online 29 July 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.